Posts Tagged ‘Talecris’

Sabine Vollmer

RTP Wrapup 11/13

Thursday, November 12, 2009, 5:24 pm By No Comments | Post a Comment

Talecris Biotherapeutics finally has money to go ahead with expansion plans in Clayton, Duke University picks Indian company to develop discoveries of its medical faculty and Pfizer will close two former Wyeth research and development centers in the Research Triangle Park area.

Read more…

Sabine Vollmer

RTP Wrapup 10/16

Thursday, October 15, 2009, 2:40 pm By No Comments | Post a Comment

GlaxoSmithKline gets hit with a $2.5 million jury verdict, Talecris borrows $550 million two weeks after going public and Affiliated Computer Services plans to hire 150 at its call center in Raleigh.

Read more…

Sabine Vollmer

RTP Wrapup 9/25

Thursday, September 24, 2009, 4:48 pm By No Comments | Post a Comment

Micell Technologies receives $15 million from St. Jude Medical, GlaxoSmithKline curbs its funding educational programs that bring doctors up-to-date, Duke Genome Center gets a $19.5 million grant and a consortium of area universities and nonprofit organizations are chasing a piece of the $63 billion the Obama Administration wants to spend over the next six years on global health care programs.

Read more…

Sabine Vollmer

Patient advocate: FTC opposition to Talecris takeover is "ridiculous"

Monday, June 1, 2009, 8:31 pm By No Comments | Post a Comment

A treatment for an inherited protein deficiency that causes lung and liver disease features prominently in the Federal Trade Commission’s request to block the $3.1 billion takeover of Talecris Biotherapeutics, one of the Research Triangle’s largest drugmakers.

Read more…

Sabine Vollmer

Complaint: Producers keep prices for blood-based drugs high

Thursday, May 28, 2009, 7:30 pm By No Comments | Post a Comment

Antitrust regulators alleged in a complaint filed Thursday that the two largest producers of four life-saving medicines made from blood plasma have figured out ways to keep prices high.

Read more…

Sabine Vollmer

Talecris sale to be blocked

Monday, May 25, 2009, 8:59 pm By No Comments | Post a Comment

The $3.1 billion offer for Talecris Biotherapeutics, one of the Triangle’s largest drugmaker, raised antitrust questions from the very beginning.

Read more…